Q4 2025 Natco Pharma Ltd Earnings Call Transcript
Key Points
- Natco Pharma Ltd (BOM:524816) recorded its highest ever consolidated revenue and profits for the financial year, with a 16% increase in revenue and a 36% increase in net profit.
- The company maintains a strong cash position of over INR3,500 crores, providing a buffer against potential headwinds.
- Natco Pharma Ltd (BOM:524816) has a robust pipeline with significant products like semaglutide and Risdiplam, which could drive future growth.
- The company is actively pursuing acquisitions to enhance its business portfolio, indicating strategic growth plans.
- Natco Pharma Ltd (BOM:524816) is investing in innovative areas such as cell and gene therapy, which could provide long-term growth opportunities.
- The company anticipates a potential 20% dip in revenue and a 30% dip in profits for FY26 due to geopolitical uncertainties and pricing pressures in the US market.
- Natco Pharma Ltd (BOM:524816) took an impairment charge of INR50 crores in its Crop Health Science business, indicating challenges in this segment.
- There is uncertainty regarding the outcome of the Risdiplam litigation, which could impact the company's ability to launch the product.
- The company faces increased R&D expenses, which could pressure margins if not offset by successful product launches.
- Natco Pharma Ltd (BOM:524816) acknowledges potential challenges in the US market due to aggressive drug price cuts and potential import tariffs.
Ladies and gentlemen, good day, and welcome to NATCO Pharma Limited Q4 FY25 earnings conference call hosted by B&K Securities. (Operator Instructions) Please note that this conference is being recorded.
I now hand the conference over to Mr. Hrishikesh Patole from B&K Securities. Thank you, and over to you, Mr. Patole.
Good morning, everyone. On behalf of B&K Securities, I welcome you all to the Q4 and full-year FY25 earnings conference call of NATCO Pharma. Hope everyone is in good health and doing well. On behalf of NATCO today, we have with us Mr. Rajeev Nannapaneni, Vice Chairman and Executive -- Chief Executive Officer; Mr. Rajesh Chebiyam, Executive Vice President, Crop Health Sciences.
I now hand over the call to Rajesh for the management's opening remarks, post which we'll open the session for Q&A. Over to you, sir.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
